Pellets for oral administration of low-molecular-weight heparin

References

• Lane DA, MacGregor IR, VanRoss M, Cella G, Kakkar VV. (1979). Molecular weight dependence of the anticoagulant properties of heparin: Intravenous and subcutaneous administration of fractionated heparins to man. Thromb Res, 16:651–62.
   PubMed Web of Science ®Google Scholar
• Weitz JI. (1997). Low-molecular-weight heparins. N Engl J Med, 337:688–98.
   PubMed Web of Science ®Google Scholar
• Kakkar AK. (2004). Low- and ultra-low-molecular-weight heparins. Best Pract Res Clin Haematol, 17:77–87.
   PubMed Web of Science ®Google Scholar
• Money SR, York JW. (2001). Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis. Cardiovasc Surg, 9:211–8.
   PubMedGoogle Scholar
• Motlekar NA, Youan BB. (2006). The quest for non-invasive delivery of bioactive macromolecules: A focus on heparins. J Control Release, 113:91–101.
   PubMed Web of Science ®Google Scholar
• Thanou M, Verhoef JC, Nihot MT, Verheijden JH, Junginger HE. (2001). Enhancement of the intestinal absorption of low molecular weight heparin (LMWH) in rats and pigs using Carbopol 934P. Pharm Res, 18:1638–41.
   PubMed Web of Science ®Google Scholar
• Bernkop-Schnurch A, Kast CE, Guggi D. (2003). Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: Thiomer/GSH systems. J Control Release, 93:95–103.
   PubMed Web of Science ®Google Scholar
• Schmitz T, Leitner VM, Bernkop-Schnurch A. (2005). Oral heparin delivery: Design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. J Pharm Sci, 94:966–73.
   PubMed Web of Science ®Google Scholar
• Motlekar NA, Srivenugopal KS, Wachtel MS, Youan BB. (2006). Evaluation of the oral bioavailability of low molecular weight heparin formulated with glycyrrhetinic acid as permeation enhancer. Drug Dev Res, 67:166–74.
   PubMed Web of Science ®Google Scholar
• Motlekar NA, Srivenugopal KS, Wachtel MS, Youan BB. (2006). Modulation of gastrointestinal permeability of low-molecular-weight heparin by l-arginine: In-vivo and in-vitro evaluation. J Pharm Pharmacol, 58:591–8.
   PubMed Web of Science ®Google Scholar
• Motlekar NA, Srivenugopal KS, Wachtel MS, Youan BB. (2005). Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels. J Drug Target, 13:573–83.
   PubMed Web of Science ®Google Scholar
• Thanou M, Henderson S, Kydonieus A, Elson C. (2007). N-sulfonato-N,O-carboxymethylchitosan: A novel polymeric absorption enhancer for the oral delivery of macromolecules. J Control Release, 117:171–8.
   PubMed Web of Science ®Google Scholar
• Rama Prasad YV, Minamimoto T, Yoshikawa Y, Shibata N, Mori S, Matsuura A, . (2004). In situ intestinal absorption studies on low molecular weight heparin in rats using labrasol as absorption enhancer. Int J Pharm, 271:225–32.
   PubMed Web of Science ®Google Scholar
• Kim SK, Lee DY, Lee E, Lee YK, Kim CY, Moon HT, . (2007). Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. J Control Release, 120:4–10.
   PubMed Web of Science ®Google Scholar
• Berkowitz SD, Marder VJ, Kosutic G, Baughman RA. (2003). Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. J Thromb Haemost, 1:1914–9.
   PubMed Web of Science ®Google Scholar
• Lever R, Page CP. (2002). Novel drug development opportunities for heparin. Nat Rev Drug Discov, 1:140–8.
   PubMed Web of Science ®Google Scholar
• Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N. (2006). Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release, 113:38–42.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Ubrich N, Hoffart V, Marchand-Arvier M, Vigneron C, Hoffman M, . (2002). Anticoagulant activity of heparin following oral administration of heparin-loaded microparticles in rabbits. J Pharm Sci, 91:760–8.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Lecompte T, . (2002). In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation, 105:230–5.
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Ubrich N, Maincent P. (2007). Oral low molecular weight heparin delivery by microparticles from complex coacervation. Eur J Pharm Biopharm, 67:632–8.
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I. (2007). Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost, 5:955–62.
   PubMed Web of Science ®Google Scholar
• Rabišková M, Pérez JP. (2002). The role of the moistering agent in the process of extrusion and spheronization. Ces Slov Farm, 51:244–7.
   PubMedGoogle Scholar
• Haring A, Vetchy D, Janovska L, Krejcova K, Rabiskova M. (2008). Differences in characteristics of pellets prepared by different pelletization methods. Drug Dev Ind Pharm, 34:289–96.
   PubMed Web of Science ®Google Scholar
• Hoffart V, Ubrich N, Lamprecht A, Bachelier K, Vigneron C, Lecompte T, . (2003). Microencapsulation of low molecular weight heparin into polymeric particles designed with biodegradable and nonbiodegradable polycationic polymers. Drug Deliv, 10:1–7.
   PubMed Web of Science ®Google Scholar
• Teien AN, Lie M. (1977). Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb Res, 10:399–410.
   PubMed Web of Science ®Google Scholar
• Vertommen J, Kinget R. (1997). The influence of five selected processing and formulation variables on the particle size, particle size distribution, and friability of pellets produced in a rotary processor. Drug Dev Ind Pharm, 23:39–46.
   Web of Science ®Google Scholar
• Rodriguez EC, Torrado JJ, Nikolakakis I, Torrado S, Lastres JL, Malamataris S. (2001). Micromeritic and packing properties of diclofenac pellets and effects of some formulation variables. Drug Dev Ind Pharm, 27:847–55.
   PubMed Web of Science ®Google Scholar
• Bianchini P, Bergonzini GL, Parma B, Osima B. (1995). Relationship between plasma antifactor Xa activity and the antithrombotic activity of heparins of different molecular mass. Haemostasis, 25:288–98.
   PubMedGoogle Scholar
• Lamprecht A, Koenig P, Ubrich N, Maincent P, Neumann D. (2006). Low molecular weight heparin nanoparticles: Mucoadhesion and behaviour in Caco-2 cells. Nanotechnology, 17:3673–80.
   Web of Science ®Google Scholar
• Jandik KA, Kruep D, Cartier M, Linhardt RJ. (1996). Accelerated stability studies of heparin. J Pharm Sci, 85:45–51.
   PubMed Web of Science ®Google Scholar
• Ahn MY, Shin KH, Kim DH, Jung EA, Toida T, Linhardt RJ, . (1998). Characterization of a bacteroides species from human intestine that degrades glycosaminoglycans. Can J Microbiol, 44:423–9.
   PubMed Web of Science ®Google Scholar
• Thanou M, Nihot MT, Jansen M, Verhoef JC, Junginger HE. (2001). Mono-N-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo. J Pharm Sci, 90:38–46.
   PubMed Web of Science ®Google Scholar
• Thanou M, Verhoef JC, Junginger HE. (2001). Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev, 52:117–26.
   PubMed Web of Science ®Google Scholar